Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Rheumatoid Arthritis: Update Bulletin [June 2015]

Product Code:
Release Date:
June 2015

Gain new KOL insights on the latest events happening in Rheumatoid Arthritis. Topics covered: new data presentations for JAK-inhibitors (such as baricitinib and filgotinib), anti-IL6 therapies (such as clazakizumab, sarilumab, and ALX 0061).

Key Questions Answered in this Update Bulletin:

  • What factors and data would be important for Baricitinib to succeed in clinical trials?
  • If approved, will baricitinib will be a threat to Pfizer’s Xeljanz (tofacitinib)?
  • Do the data from DARWIN-1 and DARWIN-2 trials indicate that Galapagos’ filgotinib is safer compare with baricitinib and/or tofacitinib?
  • What is the probability of filgotinib being used before anti-TNF therapy, as indicated by DARWIN-1 trial results?
  • How will Galapagos collaboration with AbbVie promote the development of filgotinib?
  • Does Ablynx’s anti-IL-6R nanobody ALX0061 offer any advantages over already approved Actemra (tocilizumab)?
  • What challenges will prescribers face when choosing one anti-IL6 therapy over the other, assuming Sanofi’s/Regeneron’s sarilumab, Alder’s clazakizumab and Janssen Biotech’s sirukumab reach the market?
  • Will sarilumab be successful in taking market share from Actemra?
  • What pressures will govern the shift in prescriptions from Remicade to biosimilar infliximab in EU?
  • How will the approval of subcutaneous biosimilars such as Humira and Enbrel impact the expansion of biosimilar market in RA?
  • How is the use of biosimilars viewed in the Rheumatoid Arthritis market in terms of safety, efficacy and patient accessibility to treatment?
  • Will the new autoinjector formulation of Humira successfully protect the drug against biosimilar competition?

When you purchase the full report, you get access to this Update Bulletin.

Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with the KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.


All Contents Copyright © 2020 Doctor's Guide Publishing Limited All Rights Reserved